Should You Buy Tilray Brands, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Tilray Brands, Inc. (TLRY) carries a solid Quality of Company rating of 5.9/10. Trading at $3.99, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 3 of 5 CirclFi valuation models project upside for Tilray Brands, Inc. (TLRY) at $3.99 — the model consensus leans bullish, with a Quality Score of 5.9/10 and Value-Trap risk of 31/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Tilray Brands, Inc. (TLRY) in 2026?
What Is the Bull Case vs the Bear Case for Tilray Brands, Inc. (TLRY)?
| Bull case — $13.98 target (+250.5%) | Bear case — $0.28 target (-93.0%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +64.7% across 3 bullish models from the current price of $3.99. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.28 (-93.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $13.98 (+250.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +343.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Tilray Brands, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Tilray Brands, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does TLRY Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: AQST · PRGO · VTRS · LFCR · OGI · CABR · PNXP · ZTS · LQDA · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like TLRY on Quality?
Closest companies to TLRY’s Quality of Company score of 5.9/10, across all industries.
- ARKR — Ark Restaurants Corp. (QOC 5.9) · analysis
- QUBT — Quantum Computing Inc. (QOC 5.9) · analysis
- XENE — Xenon Pharmaceuticals Inc. (QOC 5.9) · analysis
- BDN — Brandywine Realty Trust (QOC 5.9) · analysis
- HTLM — HomesToLife Ltd. (QOC 5.9) · analysis
- EYPT — EyePoint, Inc. (QOC 5.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does TLRY Appear In?
So Is Tilray Brands, Inc. (TLRY) Worth Buying in 2026?
The balance of evidence tilts cautiously positive for Tilray Brands, Inc. at $3.99. 3 of 5 models support upside to $6.57, backed by a 5.9/10 quality foundation. This is a "lean into, not load up on" setup in our framework.
These are quantitative model outputs, not investment recommendations. Tilray Brands, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TLRY Stock?
Should I buy TLRY stock right now?
Based on CirclFi's multi-model analysis, 3 of 5 models see upside for TLRY at $3.99. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.9/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Tilray Brands, Inc.?
Key risks include: limited model coverage (5/13 active), reducing analytical confidence; wide model disagreement (4916% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does TLRY compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, TLRY holds a Quality Score of 5.9/10. Comparable companies include AQST (QOC 6.0), PRGO (QOC 5.9), VTRS (QOC 6.0). The relative ranking helps investors identify whether TLRY offers better fundamental quality than alternatives in the same sector.
Is TLRY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TLRY's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy TLRY at?
CirclFi does not provide target buy prices or price alerts. However, our 5 active models produce fair value estimates ranging from $0.28 to $13.98. At $3.99, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TLRY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad